@article{65607c44513f4a4ead04f20819691298,
title = "Shifting paradigms in the systemic management of hepatocellular carcinoma",
author = "Pinato, \{David J.\}",
note = "Funding Information: I have received lecture fees from ViiV Healthcare and Bayer Healthcare, travel expenses from Bristol-Myers Squibb and Bayer Healthcare, consulting fees for Mina Therapeutics, Eisai, Roche, and AstraZeneca, and research funding (to my institution) from Merck Sharp \& Dohme and Bristol-Myers Squibb. I would like to acknowledge the Imperial College National Institute for Health Research Biomedical Research Centre and Cancer Research UK Imperial Centre for infrastructural and grant funding support. I am supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and by Cancer Research UK for the immune phenotyping of hepatocellular carcinoma (postdoctoral bursary grant reference C57701/A26137).",
year = "2020",
month = oct,
doi = "10.1016/S2468-1253(20)30250-8",
language = "English",
volume = "5",
pages = "883--885",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Ltd.",
number = "10",
}